

110TH CONGRESS
1ST SESSION

S. 2219

To amend title XVIII of the Social Security Act to deliver a meaningful benefit and lower prescription drug prices under the Medicare Program.

IN THE SENATE OF THE UNITED STATES

OCTOBER 23, 2007

Mr. DURBIN (for himself, Mr. AKAKA, Ms. STABENOW, Mrs. BOXER, and Mr. OBAMA) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XVIII of the Social Security Act to deliver a meaningful benefit and lower prescription drug prices under the Medicare Program.

1 *Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medicare Prescription
5 Drug Savings and Choice Act of 2007”.

1 SEC. 2. ESTABLISHMENT OF MEDICARE OPERATED PRE-
2SCRIPTION DRUG PLAN OPTION.

3 (a) IN GENERAL.—Subpart 2 of part D of the Social
4 Security Act is amended by inserting after section 1860D–
5 11 (42 U.S.C. 1395w–111) the following new section:

8 "SEC 1860D-11A (a) I

8 "SEC. 1860D-11A. (a) IN GENERAL.—Notwith-
9 standing any other provision of this part, for each year
10 (beginning with 2009), in addition to any plans offered
11 under section 1860D-11, the Secretary shall offer one or
12 more medicare operated prescription drug plans (as de-
13 fined in subsection (c)) with a service area that consists
14 of the entire United States and shall enter into negotia-
15 tions in accordance with subsection (b) with pharma-
16 ceutical manufacturers to reduce the purchase cost of cov-
17 ered part D drugs for eligible part D individuals who en-
18 roll in such a plan.

19 "(b) NEGOTIATIONS.—Notwithstanding section
20 1860D-11(i), for purposes of offering a medicare operated
21 prescription drug plan under this section, the Secretary
22 shall negotiate with pharmaceutical manufacturers with
23 respect to the purchase price of covered part D drugs in
24 a Medicare operated prescription drug plan and shall en-
25 courage the use of more affordable therapeutic equivalents
26 to the extent such practices do not override medical neces-

1 sity as determined by the prescribing physician. To the
2 extent practicable and consistent with the previous sen-
3 tence, the Secretary shall implement strategies similar to
4 those used by other Federal purchasers of prescription
5 drugs, and other strategies, including the use of a for-
6 mulary and formulary incentives in subsection (e), to re-
7 duce the purchase cost of covered part D drugs.

8 “(c) MEDICARE OPERATED PRESCRIPTION DRUG
9 PLAN DEFINED.—For purposes of this part, the term
10 ‘medicare operated prescription drug plan’ means a pre-
11 scription drug plan that offers qualified prescription drug
12 coverage and access to negotiated prices described in sec-
13 tion 1860D-2(a)(1)(A). Such a plan may offer supple-
14 mental prescription drug coverage in the same manner as
15 other qualified prescription drug coverage offered by other
16 prescription drug plans.

17 “(d) MONTHLY BENEFICIARY PREMIUM.—

18 “(1) QUALIFIED PRESCRIPTION DRUG COV-
19 ERAGE.—The monthly beneficiary premium for
20 qualified prescription drug coverage and access to
21 negotiated prices described in section 1860D-
22 (a)(1)(A) to be charged under a medicare operated
23 prescription drug plan shall be uniform nationally.
24 Such premium for months in 2009 and each suc-
25 ceeding year shall be based on the average monthly

1 per capita actuarial cost of offering the medicare op-
2 erated prescription drug plan for the year involved,
3 including administrative expenses.

4 “(2) SUPPLEMENTAL PRESCRIPTION DRUG COV-
5 ERAGE.—Insofar as a medicare operated prescrip-
6 tion drug plan offers supplemental prescription drug
7 coverage, the Secretary may adjust the amount of
8 the premium charged under paragraph (1).

9 “(e) USE OF A FORMULARY AND FORMULARY INCEN-
10 TIVES.—

11 “(1) IN GENERAL.—With respect to the oper-
12 ation of a medicare operated prescription drug plan,
13 the Secretary shall establish and apply a formulary
14 (and may include formulary incentives described in
15 paragraph (2)(C)(ii)) in accordance with this sub-
16 section in order to—

17 “(A) increase patient safety;
18 “(B) increase appropriate use and reduce
19 inappropriate use of drugs; and
20 “(C) reward value.

21 “(2) DEVELOPMENT OF INITIAL FORMULARY.—
22 “(A) IN GENERAL.—In selecting covered
23 part D drugs for inclusion in a formulary. the
24 Secretary shall consider clinical benefit and
25 price.

1 “(B) ROLE OF AHRQ.—The Director of the
2 Agency for Healthcare Research and Quality
3 shall be responsible for assessing the clinical
4 benefit of covered part D drugs and making
5 recommendations to the Secretary regarding
6 which drugs should be included in the for-
7 mulary. In conducting such assessments and
8 making such recommendations, the Director
9 shall—

10 “(i) consider safety concerns including
11 those identified by the Federal Food and
12 Drug Administration;

13 “(ii) use available data and evalua-
14 tions, with priority given to randomized
15 controlled trials, to examine clinical effec-
16 tiveness, comparative effectiveness, safety,
17 and enhanced compliance with a drug regi-
18 men;

19 “(iii) use the same classes of drugs
20 developed by United States Pharmacopeia
21 for this part;

22 “(iv) consider evaluations made by—

23 “(I) the Director under section
24 1013 of Medicare Prescription Drug,

1 Improvement, and Modernization Act
2 of 2003;

3 “(II) other Federal entities, such
4 as the Secretary of Veterans Affairs;
5 and

6 “(III) other private and public
7 entities, such as the Drug Effectiveness
8 Review Project and Medicaid
9 programs; and

10 “(v) recommend to the Secretary—

11 “(I) those drugs in a class that
12 provide a greater clinical benefit, in-
13 cluding fewer safety concerns or less
14 risk of side-effects, than another drug
15 in the same class that should be in-
16 cluded in the formulary;

17 “(II) those drugs in a class that
18 provide less clinical benefit, including
19 greater safety concerns or a greater
20 risk of side-effects, than another drug
21 in the same class that should be ex-
22 cluded from the formulary; and

23 “(III) drugs in a class with same
24 or similar clinical benefit for which it
25 would be appropriate for the Sec-

retary to competitively bid (or negotiate) for placement on the formulary.

“(C) CONSIDERATION OF AHRQ RECOMMENDATIONS.—

“(i) IN GENERAL.—The Secretary, after taking into consideration the recommendations under subparagraph (B)(v), shall establish a formulary, and formulary incentives, to encourage use of covered part D drugs that—

"(I) have a lower cost and provide a greater clinical benefit than other drugs;

"(II) have a lower cost than other drugs with same or similar clinical benefit; and

"(III) drugs that have the same cost but provide greater clinical benefit than other drugs.

"(ii) FORMULARY INCENTIVES.—The formulary incentives under clause (i) may be in the form of one or more of the following:

“(I) Tiered copayments.

“(II) Reference pricing.

1 “(III) Prior authorization.

2 “(IV) Step therapy.

3 “(V) Medication therapy manage-

4 ment.

5 “(VI) Generic drug substitution.

6 “(iii) FLEXIBILITY.—In applying such

7 formulary incentives the Secretary may de-

8 cide not to impose any cost-sharing for a

9 covered part D drug for which—

10 “(I) the elimination of cost shar-

11 ing would be expected to increase

12 compliance with a drug regimen; and

13 “(II) compliance would be ex-

14 pected to produce savings under part

15 A or B or both.

16 “(3) LIMITATIONS ON FORMULARY.—In any

17 formulary established under this subsection, the for-

18 mulary may not be changed during a year, except—

19 “(A) to add a generic version of a covered

20 part D drug that entered the market;

21 “(B) to remove such a drug for which a

22 safety problem is found; and

23 “(C) to add a drug that the Secretary

24 identifies as a drug which treats a condition for

25 which there has not previously been a treatment

1 option or for which a clear and significant ben-
2 efit has been demonstrated over other covered
3 part D drugs.

4 “(4) ADDING DRUGS TO THE INITIAL FOR-
5 MULARY.—

10 “(i) to review petitions from drug
11 manufacturers, health care provider orga-
12 nizations, patient groups, and other enti-
13 ties for inclusion of a drug in, or other
14 changes to, such formulary; and

18 “(B) COMPOSITION.—The advisory com-
19 mittee shall be composed of 9 members and
20 shall include representatives of physicians,
21 pharmacists, and consumers and others with ex-
22 pertise in evaluating prescription drugs. The
23 Secretary shall select members based on their
24 knowledge of pharmaceuticals and the Medicare
25 population. Members shall be deemed to be spe-

1 eial Government employees for purposes of ap-
2 plying the conflict of interest provisions under
3 section 208 of title 18, United States Code, and
4 no waiver of such provisions for such a member
5 shall be permitted.

6 “(C) CONSULTATION.—The advisory com-
7 mittee shall consult, as necessary, with physi-
8 cians who are specialists in treating the disease
9 for which a drug is being considered.

10 “(D) REQUEST FOR STUDIES.—The advi-
11 sory committee may request the Agency for
12 Healthcare Research and Quality or an aca-
13 demic or research institution to study and make
14 a report on a petition described in subpara-
15 graph (A)(ii) in order to assess—

16 “(i) clinical effectiveness;
17 “(ii) comparative effectiveness;
18 “(iii) safety; and
19 “(iv) enhanced compliance with a
20 drug regimen.

21 “(E) RECOMMENDATIONS.—The advisory
22 committee shall make recommendations to the
23 Secretary regarding—

24 “(i) whether a covered part D drug is
25 found to provide a greater clinical benefit,

1 including fewer safety concerns or less risk
2 of side-effects, than another drug in the
3 same class that is currently included in the
4 formulary and should be included in the
5 formulary;

6 “(ii) whether a covered part D drug is
7 found to provide less clinical benefit, in-
8 cluding greater safety concerns or a great-
9 er risk of side-effects, than another drug in
10 the same class that is currently included in
11 the formulary and should not be included
12 in the formulary; and

13 “(iii) whether a covered part D drug
14 has the same or similar clinical benefit to
15 a drug in the same class that is currently
16 included in the formulary and whether the
17 drug should be included in the formulary.

18 “(F) LIMITATIONS ON REVIEW OF MANU-
19 FACTURER PETITIONS.—The advisory com-
20 mittee shall not review a petition of a drug
21 manufacturer under subparagraph (A)(ii) with
22 respect to a covered part D drug unless the pe-
23 petition is accompanied by the following:

24 “(i) Raw data from clinical trials on
25 the safety and effectiveness of the drug.

1 “(ii) Any data from clinical trials con-
2 ducted using active controls on the drug or
3 drugs that are the current standard of
4 care.

5 “(iii) Any available data on compara-
6 tive effectiveness of the drug.

7 “(iv) Any other information the Sec-
8 retary requires for the advisory committee
9 to complete its review.

10 “(G) RESPONSE TO RECOMMENDATIONS.—

11 The Secretary shall review the recommenda-
12 tions of the advisory committee and if the Sec-
13 retary accepts such recommendations the Sec-
14 retary shall modify the formulary established
15 under this subsection accordingly. Nothing in
16 this section shall preclude the Secretary from
17 adding to the formulary a drug for which the
18 Director of the Agency for Healthcare Research
19 and Quality or the advisory committee has not
20 made a recommendation.

21 “(H) NOTICE OF CHANGES.—The Sec-
22 retary shall provide timely notice to bene-
23 ficiaries and health professionals about changes
24 to the formulary or formulary incentives.

1 “(f) INFORMING BENEFICIARIES.—The Secretary
2 shall take steps to inform beneficiaries about the avail-
3 ability of a Medicare operated drug plan or plans including
4 providing information in the annual handbook distributed
5 to all beneficiaries and adding information to the official
6 public Medicare website related to prescription drug cov-
7 erage available through this part.

8 “(g) APPLICATION OF ALL OTHER REQUIREMENTS
9 FOR PRESCRIPTION DRUG PLANS.—Except as specifically
10 provided in this section, any Medicare operated drug plan
11 shall meet the same requirements as apply to any other
12 prescription drug plan, including the requirements of sec-
13 tion 1860D-4(b)(1) relating to assuring pharmacy ac-
14 cess.”.

15 (b) CONFORMING AMENDMENTS.—

16 (1) Section 1860D-3(a) of the Social Security
17 Act (42 U.S.C. 1395w-103(a)) is amended by add-
18 ing at the end the following new paragraph:

19 “(4) AVAILABILITY OF THE MEDICARE OPER-
20 ATED PRESCRIPTION DRUG PLAN.—A medicare oper-
21 ated prescription drug plan (as defined in section
22 1860D-11A(e)) shall be offered nationally in accord-
23 ance with section 1860D-11A.”.

10 “(8) NO AUTHORITY FOR FALBACK PLANS
11 AFTER 2008.—A fallback prescription drug plan shall
12 not be available after December 31, 2008.”.

13 (3) Section 1860D-13(c)(3) of such Act (42
14 U.S.C. 1395w-113(c)(3)) is amended—

15 (A) in the heading, by inserting "AND"
16 MEDICARE OPERATED PRESCRIPTION DRUG
17 PLANS" after "FALLBACK PLANS"; and

(B) by inserting “or a medicare operated prescription drug plan” after “a fallback prescription drug plan”.

21 (4) Section 1860D-16(b)(1) of such Act (42
22 U.S.C.1395w-116(b)(1)) is amended—

23 (A) in subparagraph (C), by striking
24 "and" after the semicolon at the end;

(B) in subparagraph (D), by striking the period at the end and inserting ";" and"; and

(C) by adding at the end the following new subparagraph:

“(E) payments for expenses incurred with respect to the operation of medicare operated prescription drug plans under section 1860D–11A.”.

(5) Section 1860D-41(a) of such Act (42 U.S.C. 1395w-151(a)) is amended by adding at the end the following new paragraph:

“(19) MEDICARE OPERATED PRESCRIPTION DRUG PLAN.—The term ‘medicare operated prescription drug plan’ has the meaning given such term in section 1860D-11A(c).”.

16 (c) EFFECTIVE DATE.—The amendments made by
17 this section shall take effect as if included in the enact-
18 ment of section 101 of the Medicare Prescription Drug,
19 Improvement, and Modernization Act of 2003.

20 SEC. 3. IMPROVED APPEALS PROCESS UNDER THE MEDI-
21 CARE OPERATED PRESCRIPTION DRUG PLAN.

22 Section 1860D-4(h) of the Social Security Act (42
23 U.S.C. 1305w-104(h)) is amended by adding at the end
24 the following new paragraph:

1 “(h) APPEALS PROCESS FOR MEDICARE OPERATED
2 PRESCRIPTION DRUG PLAN.—

3 “(1) IN GENERAL.—The Secretary shall develop
4 a well-defined process for appeals for denials of ben-
5 efits under this part under the medicare operated
6 prescription drug plan. Such process shall be effi-
7 cient, impose minimal administrative burdens, and
8 ensure the timely procurement of non-formulary
9 drugs or exemption from formulary incentives when
10 medically necessary. Medical necessity shall be based
11 on professional medical judgment, the medical condi-
12 tion of the beneficiary, and other medical evidence.
13 Such appeals process shall include—

14 “(A) an initial review and determination
15 made by the Secretary; and

16 “(B) for appeals denied during the initial
17 review and determination, the option of an ex-
18 ternal review and determination by an inde-
19 pendent entity selected by the Secretary.

20 “(2) CONSULTATION IN DEVELOPMENT OF
21 PROCESS.—In developing the appeals process under
22 paragraph (1), the Secretary shall consult with con-
23 sumer and patient groups, as well as other key
24 stakeholders to ensure the goals described in para-
25 graph (1) are achieved.”.

1 SEC. 4. PHARMACY PAYMENT UNDER THE MEDICARE OP-

2 ERATED PRESCRIPTION DRUG PLAN.

3 Section 1860D-12(b) of the Social Security Act (42
4 U.S.C. 1395w-112 (b)) is amended by adding at the end
5 the following new paragraph:6 "(4) PHARMACY PAYMENT UNDER THE MEDI-
7 CARE OPERATED PRESCRIPTION DRUG PLAN.—8 "(A) IN GENERAL.—Under the medicare
9 operated prescription drug plan, the Secretary
10 shall develop a system for payment to phar-
11 macies. Such a system shall include a require-
12 ment that the plan shall issue, mail, or other-
13 wise transmit payment for all clean claims sub-
14 mitted under this part within the applicable
15 number of calendar days after the date on
16 which the claim is received.

17 "(B) DEFINITIONS.—In this paragraph:

18 "(i) CLEAN CLAIM.—The term 'clean
19 claim' means a claim, with respect to a
20 covered part D drug, that has no apparent
21 defect or impropriety (including any lack
22 of any required substantiating documen-
23 tation) or particular circumstance requiring
24 special treatment that prevents timely pay-
25 ment from being made on the claim under
26 this part.

1 “(ii) APPLICABLE NUMBER OF CAL-

2 ENDAR DAYS.—The term ‘applicable num-
3 ber of calendar days’ means—

4 “(I) with respect to claims sub-
5 mitted electronically, 14 calendar
6 days; and

7 “(II) with respect to claims sub-
8 mitted otherwise, 30 calendar days.

9 “(C) PROCEDURES INVOLVING CLAIMS.—

10 “(i) CLAIMS DEEMED TO BE CLEAN
11 CLAIMS.—

12 “(I) IN GENERAL.—A claim for a
13 covered part D drug shall be deemed
14 to be a clean claim for purposes of
15 this paragraph if the Secretary does
16 not provide a notification of deficiency
17 to the claimant by the 10th day that
18 begins after the date on which the
19 claim is submitted.

20 “(II) NOTIFICATION OF DEFI-
21 CIENCY.—For purposes of subclause
22 (I), the term ‘notification of defi-
23 ciency’ means a notification that
24 specifies all defects or improprieties in
25 the claim involved and that lists all

1 additional information or documents
2 necessary for the proper processing
3 and payment of the claim.

4 “(ii) PAYMENT OF CLEAN PORTIONS
5 OF CLAIMS.—The Secretary shall, as ap-
6 propriate, pay any portion of a claim for a
7 covered part D drug under the medicare
8 operated prescription drug plan that would
9 be a clean claim but for a defect or impro-
10 priety in a separate portion of the claim in
11 accordance with subparagraph (A).

12 “(iii) OBLIGATION TO PAY.—A claim
13 for a covered part D drug submitted to the
14 Secretary that is not paid or contested by
15 the provider within the applicable number
16 of calendar days (as defined in subpara-
17 graph (B)) shall be deemed to be a clean
18 claim and shall be paid by the Secretary in
19 accordance with subparagraph (A).

20 “(iv) DATE OF PAYMENT OF CLAIM.—
21 Payment of a clean claim under subpara-
22 graph (A) is considered to have been made
23 on the date on which full payment is re-
24 ceived by the provider.



20 3 8095 00010257 0

1 “(D) ELECTRONIC TRANSFER OF
2 FUNDS.—The Secretary shall pay all clean
3 claims submitted electronically by an electronic
4 funds transfer mechanism.”.

○